Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ IgG positive 27% unadjusted Improvement Relative Risk c19hcq.org Mahto et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 689 patients in India Lower IgG positivity with HCQ (not stat. sig., p=0.38) Mahto et al., American J. Blood Research, 11:1 Favors HCQ Favors control
Seroprevalence of IgG against SARS-CoV-2 and its determinants among healthcare workers of a COVID-19 dedicated hospital of India
Mahto et al., American Journal of Blood Research, 11:1
Mahto et al., Seroprevalence of IgG against SARS-CoV-2 and its determinants among healthcare workers of a COVID-19 dedicated.., American Journal of Blood Research, 11:1
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 689 healthcare workers in India, showing no significant difference in IgG positivity with HCQ prophylaxis in unadjusted results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of IgG positive, 26.9% lower, RR 0.73, p = 0.38, treatment 9 of 89 (10.1%), control 84 of 600 (14.0%), NNT 26, unadjusted, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mahto et al., 15 Feb 2021, retrospective, India, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Am J Blood Res 2021;11(1):44-52 www.AJBlood.us /ISSN:2160-1992/AJBR0128941 Original Article Seroprevalence of IgG against SARS-CoV-2 and its determinants among healthcare workers of a COVID-19 dedicated hospital of India Mala Mahto1, Ayan Banerjee1, Bijit Biswas2, Sushil Kumar1, Neeraj Agarwal2, Prabhat Kumar Singh3 Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India; 2Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India; 3Department of Anaesthesiology and Critical Care, Director, All India Institute of Medical Sciences, Patna, Bihar, India 1 Received December 24, 2020; Accepted January 27, 2021; Epub February 15, 2021; Published February 28, 2021 Abstract: Healthcare workers (HCWs) due to their job profile are at utmost risk of contracting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Serological survey is an useful tool for vulnerability mapping in an infectious disease pandemic. The aim of the current study was to assess seroprevalence of IgG against SARSCoV-2 and its determinants among HCWs of a tertiary healthcare facility of India. It was an observational study, cross-sectional in design conducted among 919 HCWs of All India Institute of Medical Sciences, Patna, Bihar, India during September, 2020. In results, IgG seroprevalence for SARS-CoV-2 among the study subjects was 13.3% [95% confidence interval (CI): 11.2-15.6%]. In univariate logistic regression analysis; gender, occupation, place of posting, use of full personal protective equipment (PPE), prior corona virus disease (COVID)-19 infection, influenza like illness (ILI), use of steam inhalation, consumption of azithromycin, zinc and vitamin C were the significant attributes which affected the IgG seropositivity for SARS-CoV-2. In the multivariable logistic regression model; occupation, place of posting, prior COVID-19 infection and ILI were significant determinants of IgG seropositivity for SARS-CoV-2. To conclude, majority of the HCWs were found to be IgG seronegative for SARS-CoV-2. Till availability of effective vaccine all of the HCWs should abide by infection prevention and control (IPC) measures to keep themselves and their contacts protected from SARS-CoV-2. Keywords: COVID-19, immunoglobulin G, seroepidemiologic studies, health personnel, epidemiologic factors
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit